Effect of Hyperuricaemia on Chronic Renal Disease

The Affiliated Hospital of Xuzhou Medical University400 enrolled

Overview

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate that low levels of serum uric acid can delay the progression of renal damage. Promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of CKD in patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

400

Conditions

Hyperuricemia Chronic Renal Disease

Interventions

20mg FebuxostatDRUG

Participants take 20mg febuxostat pill once a day for at least six months.

40mg FebuxostatDRUG

Participants take 40mg febuxostat pill once a day for at least six months.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-dialysis CKD patients with serum uric acid greater than 7mg/dl. * eGFR≥15ml/min/1.73m². * Low salt, low protein, low purine diet. Exclusion Criteria: * Take drugs that raise blood uric acid at the same time. * Patients with gout attacks. * Patients with pregnant, lactating. * Autosomal dominant polycystic kidney disease. * Patients with poor general condition and multiple organ failure.

Locations (1)

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

serum uric acid

intravenous blood sampling

Time frame: up to 6 months

Secondary Outcomes

serum creatinine

intravenous blood sampling

Time frame: up to 6 months

Central Contacts

Dong Sun, MD

CONTACT

15862158578 sundong126@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.